US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Generate Biomedicines (GENB): Flagship Backed Programmable Biology Company Drawing IPO Interest

Generate Biomedicines (GENB): Valuation Pushback Hits Flagship-Backed AI Biotech Company

Generate Biomedicines (GENB): Post 180-Days, From IPO Disaster to a Remarkable Recovery

Generate Biomedicines (GENB): Peeking at the IPO Prospectus of an AI Biotech Company

IPOs and Secondary Offerings

Equity Capital Markets

Generate Biomedicines / Equity Capital Markets

<ul>
<li>Generate Biomedicines plans to offer 25.0M shares at $15–$17, targeting a $1.9B–$2.2B market cap ahead of its February 27 debut.</li>
<li>IPO proceeds of ~$369M (midpoint) will fund Phase 3 asthma trials, COPD expansion, oncology programs, and continued platform innovation.</li>
<li>Backed by Flagship and major tech/life sciences investors, the AI-driven protein design platform enters public markets with strategic collaborations and late-stage momentum.</li>
</ul>


Generate Biomedicines plans to offer 25.0M shares at $15–$17, targeting a $1.9B–$2.2B market cap ahead of its February 27 debut.
IPO proceeds of ~$369M (midpoint) will fund Phase 3 asthma trials, COPD expansion, oncology programs, and continued platform innovation.
Backed by Flagship and major tech/life sciences investors, the AI-driven protein design platform enters public markets with strategic collaborations and late-stage momentum.


Generate Biomedicines (GENB): AI Biotech Sets Terms for IPO, Seeking $2.2b Valuation